Abstract

Provided herein are genetically engineered Pichinde viruses that include three ambisense genomic segments. Two of the genomic segments include an additional coding region that may encode one or more swine influenza virus (SIV) proteins, such as a SIV hemagglutinin (HA) protein. SIV HA proteins can be from different subtypes of SIV. Also provided herein is a reverse genetics system for making genetically engineered Pichinde virus, and a collection of vectors that can be used to produce genetically engineered Pichinde virus. Further provided are methods for using a reverse genetics system, and methods for treating a SIV infection in a subject.

IPC Classes  ?

• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 37/04 - Immunostimulants
• C12N 15/86 - Viral vectors

Abstract

Articles and method of making articles including a solid porous material having a selenium nanomaterial bound to a surface of and within the solid porous material. The article may be a include no polymeric stabilizer or proteinaceous stabilizer. The solid porous material may be a sponge, a film, a fabric, a non-woven material, or a metal-organic framework (MOF), or a combination thereof. The article may be produced by treating a solid porous material with an aqueous selenous acid solution and heating the solid porous material to form the selenium nanomaterial on the surface of and within the solid porous material.

IPC Classes  ?

• B01J 20/02 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material
• A01N 59/02 - SulfurSeleniumTelluriumCompounds thereof
• B01D 53/02 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography
• B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties
• B01J 20/32 - Impregnating or coating
• C01B 19/02 - Elemental selenium or tellurium
• C02F 1/28 - Treatment of water, waste water, or sewage by sorption
• C02F 101/20 - Heavy metals or heavy metal compounds
• C02F 103/00 - Nature of the water, waste water, sewage or sludge to be treated

Abstract

The invention provides antibiotic BPI Fold Containing Family A Member 2 (BPIFA2) peptides, compositions comprising a BPIFA2 peptide, hydrogels comprising a BPIFA2 peptide, nanofibrillar networks comprising a BPIFA2 peptide, and tissue scaffolds comprising BPIFA2 peptides. The peptide, compositions, hydrogels nanofibrillar networks and tissue scaffolds are useful for medical therapy in an animal.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers

Abstract

A magnetic tissue stimulator 100 comprising a coil 106, a first magnetic layer 122 having a first end 127 and a second end 123 and a second magnetic layer 124 having a first end 129 and a second end 125. The second end 123 of the first magnetic layer 122 is in contact 126 with the second end 125 of the second magnetic layer 124 and the first end 127 of the first magnetic layer 122 is separated from the first end 129 of the second magnetic layer 124 by a gap 128. A portion of the coil 106 is positioned between the first magnetic layer 122 and the second magnetic layer 124.

IPC Classes  ?

• A61N 2/02 - Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets
• A61N 2/08 - Magnetotherapy using magnetic fields produced by permanent magnets applied externally
• A61N 2/06 - Magnetotherapy using magnetic fields produced by permanent magnets
• A61N 2/12 - Magnetotherapy using variable magnetic fields obtained by mechanical movement

Abstract

Methods for facilitating drug discovery in various models and proposing single cell-type-specific drug candidates, and predicting cellular drug sensitivities. Predictions comprise obtaining bulk RNA sequence data, wherein bulk RNA seq data is pan-cancer cell line transcriptomic data from one or more sources; obtaining single cell RNA sequence data (scRNA-seq) from one or more sources; integrating the bulk RNA sequence data and scRNA-seq data; capturing similarities between the bulk data and the scRNA-seq data based on a shared drug response relative gene and using canonical correlation analysis; extracting one or more drug-response relevant features and selecting a pharmacogenomic subspace for accurately predicting a single-cell drug response.

IPC Classes  ?

• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation
• G16B 40/20 - Supervised data analysis

Abstract

A system for Multi-Party Computation (MPC) includes a general-purpose programming language, an MPC processor, an MPC Instruction Set Architecture (ISA), and a compiler. The general-purpose programming language is used for writing an MPC application. The MPC processor executes the MPC application. The MPC ISA corresponds to the MPC processor. The compiler generates an intermediate representation for the MPC application and generates machine code for the intermediate representation by mapping and assembling MPC ISA instructions.

IPC Classes  ?

• G06F 9/38 - Concurrent instruction execution, e.g. pipeline or look ahead
• G06F 9/30 - Arrangements for executing machine instructions, e.g. instruction decode

Abstract

This disclosure describes methods for organoid generation including, for example, for generation of a multi-tissue organoid. The multi-tissue organoid may include cartilage, bone, epithelium, and/or fibrous connective tissue. This disclosure further describes methods for isolating cells from the organoids and methods of using the organoids and cells of the organoids.

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells

Abstract

Denoised magnetic resonance images are generated using a two-step process. An initial set of images is first denoised on a per channel basis using a locally low-rank-based denoising technique. The denoised coil channel images are transformed back into k-space and the denoised k-space data are then applied to a nonlinear image reconstruction. In some instances, the nonlinear image reconstruction can be implemented using a trained neural network. The neural network may be trained using a self-supervised learning technique.

IPC Classes  ?

• G06T 11/00 - 2D [Two Dimensional] image generation
• G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
• G06T 5/70 - DenoisingSmoothing

Abstract

The disclosure provides a method of treating or reducing the risk of developing an alloimmune condition or an autoimmune condition in a subject in need thereof. The method comprises (a) measuring CD83 in a population of immune cells from the subject, and (b) administering to the subject a CD83-targeted therapeutic.

IPC Classes  ?

• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The present disclosure relates, in general, to non-viral methods for generating engineered B cell, and use of such B cells as cell-based therapeutics to treat disease.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C12N 5/0781 - B cellsProgenitors thereof
• C12N 9/22 - Ribonucleases
• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
• C12N 15/86 - Viral vectors
• C12N 15/90 - Stable introduction of foreign DNA into chromosome

Abstract

Materials and methods for gene editing using improved targeted endonucleases and endonuclease systems (e.g., Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) endonuclease systems) are provided herein.

IPC Classes  ?

• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Abstract

A stent for a respiratory organ includes a bioabsorbable polyester copolymer. The bioabsorbable polyester copolymer is a polyester copolymer having residues of two kinds of ester bond forming monomers as main constituent units, and where the two kinds of ester bond forming monomers are referred to as monomer A and monomer B, respectively, an R value given by the following formula is 0.25 or larger and 0.99 or smaller: R=[AB]/(2[A][B]) 100. In the formula, [A] is a mole fraction (%) of monomer A residues in the polyester copolymer; [B] is a mole fraction (%) of monomer B residues in the polyester copolymer; and [AB] is a mole fraction (%) of structures (A-B and B-A) in which a monomer A residue and a monomer B residue are adjacent to each other in the polyester copolymer.

IPC Classes  ?

• A61F 2/04 - Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
• A61L 27/18 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• A61L 27/58 - Materials at least partially resorbable by the body

Abstract

Binding proteins derived from parental protein that bind to a target. The binding proteins may bind to the target with a dissociation constant of 1 micromolar or less. The parental protein may have a variety of secondary structures and tertiary structures. Screening proteins and screening methos of screening the screening proteins.

IPC Classes  ?

• C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C40B 40/10 - Libraries containing peptides or polypeptides, or derivatives thereof

Abstract

Parallel transmit (“pTx”) radio frequency (“RF”) pulses, or other RF pulse types, for use in magnetic resonance imaging (“MRI”) are designed using deep learning techniques. In some aspects, deep learning can be used to determine optimization parameters for improving the computational efficiency of solving a physics-based constrained optimization problem for generating RF pulse waveforms. In some other aspects, deep learning can be used to learn a mapping from magnetic resonance data obtained with an MRI system to pTx RF pulse waveforms in a data-driven manner. The mapping can be based on field map data that are inherently encoded in scout images without having to explicitly calculate the field maps, or may be based on multichannel B1+ maps that are concatenated along one spatial dimension, such as the y-dimension.

IPC Classes  ?

• G01R 33/54 - Signal processing systems, e.g. using pulse sequences
• G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques

Abstract

Techniques are described for automated microinjection of substances, such as genetic material, into microscopic objects, such as embryos. An example system includes a pressure controller, a stereoscopic imaging apparatus, a first camera, a second camera, and a computing system. The computing system is configured to apply one or more computer vision algorithms that determine, based on image data generated by the stereoscopic imaging apparatus, first camera, and second camera, a location of a tip of a micropipette and a location of a particular microscopic object in three-dimensional space. The computing system is further configured to control the pressure controller to cause the micropipette to eject the substance from the tip of the micropipette and into the particular microscopic object.

IPC Classes  ?

• G06T 7/73 - Determining position or orientation of objects or cameras using feature-based methods
• G06T 3/40 - Scaling of whole images or parts thereof, e.g. expanding or contracting

Abstract

The present invention is directed to methods of probiotic selection and use based on the capability of microbial biogenic amine uptake as a method for targeted clinical and veterinary applications, including promoting health and well-being and/or treating therapeutic conditions. The present invention utilizes a microbially-focused approach for the development of drug selection and/or probiotic administration in a variety of diseases and disorders.

IPC Classes  ?

• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
• A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor

Abstract

A biofilm composition includes a biofilm encapsulated within an encapsulant. In one or more embodiments, the biofilm includes a support material and a community of microorganisms. In one or more of these embodiments, the material supporting the biofilm includes biochar or powdered activated carbon. The composition may be used to treat wastewater.

IPC Classes  ?

• C02F 3/34 - Biological treatment of water, waste water, or sewage characterised by the microorganisms used
• C02F 3/00 - Biological treatment of water, waste water, or sewage
• C02F 3/28 - Anaerobic digestion processes
• C02F 103/32 - Nature of the water, waste water, sewage or sludge to be treated from the food or foodstuff industry, e.g. brewery waste waters

Abstract

A medical apparatus generally includes a data interface configured to receive measurements, and a processor coupled to the data interface. The processor is configured with instructions operable to receive lung active compound measurements after a baseline dose of a lung active compound has been administered to a subject, facilitate providing adjusted dosages of a lung active compound to the subject via a drug dispenser until the lung active compound measurements reach an inflection point that indicates efficacy of the dosages of a lung active compound, and facilitate administering a constant dosage of a lung active compound after the efficacy is indicated. The apparatus may be instructed to receive measurements of biomarkers and adjust dosages of a lung active compound based, at least in part, on the biomarker measurements.

IPC Classes  ?

• G01N 33/78 - Thyroid gland hormones
• G06N 20/00 - Machine learning
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61M 11/00 - Sprayers or atomisers specially adapted for therapeutic purposes

Abstract

Disclosed herein are methods and systems of operating an ammonia combustion system, including heating a first reactor of the ammonia combustion system to a first temperature value; flowing a first fuel to the first reactor, the first fuel including ammonia; reforming the first fuel into a second fuel; providing the second fuel to an intake of the ammonia combustion system; allowing the second fuel to combust in the ammonia combustion system thereby generating an exhaust gas; and flowing the exhaust gas from an exhaust along outer surfaces of a second reactor of the ammonia combustion system; wherein, when the second temperature exceeds a threshold temperature value, the flow of the first fuel to the first reactor is terminated.

IPC Classes  ?

• F02D 19/06 - Controlling engines characterised by their use of non-liquid fuels, pluralities of fuels, or non-fuel substances added to the combustible mixtures peculiar to engines working with pluralities of fuels, e.g. alternatively with light and heavy fuel oil, other than engines indifferent to the fuel consumed
• F02D 21/02 - Controlling engines characterised by their being supplied with non-airborne oxygen or other non-fuel gas peculiar to oxygen-fed engines

Abstract

In one aspect, the present disclosure relates to a fusion protein including an affinity moiety; an HUH tag; and an oligonucleotide, wherein the oligonucleotide is covalently bound by the HUH tag. The HUH tag and the affinity moiety may be connected by an amino acid linkage or chemically attached. In one or more embodiments, the affinity moiety includes an intermediate binder protein and an affinity moiety of interest. In another aspect, the present disclosure relates to a method of preparing such a fusion protein. In another aspect, the present disclosure relates to a method of detecting presence of a molecule in a sample.

IPC Classes  ?

• C07K 19/00 - Hybrid peptides
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C12P 21/00 - Preparation of peptides or proteins
• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• B82Y 15/00 - Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA

Abstract

The present disclosure provides compounds of Formula I which can be tuned to provide agonistic or antagonistic toll-like receptor (TLR) bining properties. Further provided herein are pharmaceutical compositions comprising compounds described herein, as well as methods of using such compositions to treat a disease or condition in a subject.

IPC Classes  ?

• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• C07D 471/04 - Ortho-condensed systems

Abstract

Provided herein is a promoter sequence consisting of a nucleic acid of between 12 and 300 nucleotides in length, wherein the nucleic acid comprises a polynucleotide having at least 90% identity to SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, and/or SEQ ID NO:6. Also provided are expression cassettes and vectors comprising the novel promoters described herein, wherein the promoter is operably linked to a preselected DNA segment encoding a protein or heterologous RNA transcript. Also provided are isolated transformed cells comprising the novel expression cassette or vector described herein. Methods are also provided for producing transformed cells and for treating a genetic disorder.

IPC Classes  ?

• C12N 15/864 - Parvoviral vectors
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

Abstract

The invention provides a compound of formula (I): or a salt thereof, wherein R1has any of the values described in the specification, as well as compositions comprising a compound of formula (I). The compounds are useful as senolytic agents.

IPC Classes  ?

• C07D 311/30 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
• A61P 39/00 - General protective or antinoxious agents
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline

Abstract

Devices, systems, and techniques are described for determining toolpaths for printing constructs with microarchitecture. For example, a method includes receiving, by processing circuitry, imaging data representative of a target structure; determining, by the processing circuitry and based on the imaging data, a map of material tracks for the target structure; determining, by the processing circuitry and from the map of material tracks, one or more toolpaths for depositing material to form a construct representative of the target structure; and generating, by the processing circuitry and based on the one or more toolpaths, computer code that defines a three-dimensional (3D) printing process for a printing nozzle to deposit the material to form the construct.

IPC Classes  ?

• G05B 19/4099 - Surface or curve machining, making 3D objects, e.g. desktop manufacturing

Abstract

Bioactive coatings that are stabilized against inactivation by weathering are provided including a base associated with a chemically modified enzyme capable of enzymatically degrading a component of an organic stain, optionally a lipase or a lysozyme, and optionally a first polyoxyethylene present in the base and independent of the enzyme. The coatings are optionally overlayered onto a substrate to form an active coating facilitating the removal of organic stains or bacterial organic material.

IPC Classes  ?

• C09D 189/00 - Coating compositions based on proteinsCoating compositions based on derivatives thereof
• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• C08G 65/333 - Polymers modified by chemical after-treatment with organic compounds containing nitrogen
• C09D 5/02 - Emulsion paints
• C09D 5/16 - Anti-fouling paintsUnderwater paints
• C09D 7/40 - Additives
• C09D 175/16 - Polyurethanes having carbon-to-carbon unsaturated bonds having terminal carbon-to-carbon unsaturated bonds
• C12N 9/14 - Hydrolases (3.)
• C12N 9/20 - Triglyceride splitting, e.g. by means of lipase
• C12N 9/26 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on alpha-1, 4-glucosidic bonds, e.g. hyaluronidase, invertase, amylase
• C12N 9/54 - Proteinases derived from bacteria bacteria being Bacillus
• C12N 9/96 - Stabilising an enzyme by forming an adduct or a compositionForming enzyme conjugates
• C12N 11/06 - Enzymes or microbial cells immobilised on or in an organic carrier attached to the carrier via a bridging agent
• C12N 11/089 - Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds

Abstract

Mutant oilseed plants that exhibit increased seed size, increased seed oil content, and/or increased seed protein content are described herein.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• A01H 5/10 - Seeds
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

Disclosed herein are methods of stimulating and expanding polyclonal gamma delta T cells (GDTCs) in vitro. More specifically, anti-gamma delta T cell receptor (GDTCR) antibody is used in combination with anti-CD28 antibody and one or more of IL-2, IL-7, and IL-15 to efficiently expand GDTCs in vitro.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

The invention provides compositions and methods for treating conditions associated with decreased activity of hydrogen sulfide.

IPC Classes  ?

• A61K 31/426 - 1,3-Thiazoles
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/22 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
• A61K 31/265 - Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
• A61K 31/385 - Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
• A61K 31/554 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Pharmaceutical compositions including nervonic acid or a pharmaceutically acceptable salt thereof and a cyclodextrin. Methods of treating a subject having or at risk of having adrenoleukodystrophy and/or a neurological disease by administering a pharmaceutical composition of the present disclosure to the subject.

IPC Classes  ?

• A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
• A61K 47/40 - CyclodextrinsDerivatives thereof

Abstract

Described here are systems and methods for testing neurostimulation settings and measuring their effects on neural activity, which may then be used to select subject-specific neurostimulation settings. In general, the present disclosure provides systems and methods that utilize neural recordings to help determine the neurostimulation settings that maximally reduce a particular neural activity.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
• A61N 1/372 - Arrangements in connection with the implantation of stimulators
• G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture

Abstract

In some aspects, the present disclosure pertains to methods of treating a tissue volume comprising (a) administering an implantable composition comprising a releasable membrane-active agent to a target site such that the membrane-active agent is locally released to the tissue volume and (b) performing irreversible, reversible and/or thermal treatment by application of a pulsed electric field to the tissue volume. In other aspects, the present disclosure pertains to embolic compositions that comprise releasable membrane-active agents.

IPC Classes  ?

• A61B 18/14 - Probes or electrodes therefor
• A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof

Abstract

Citrullus lanatus are infused with mesoporous silica nanoparticles with or without the chitosan increased germination was observed.

IPC Classes  ?

• C01B 33/18 - Preparation of finely divided silica neither in sol nor in gel formAfter-treatment thereof
• A01C 1/06 - Coating or dressing seed
• C05D 9/00 - Other inorganic fertilisers
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

The present document relates to systems that employ photoelectrocatalysis, as well as methods using photoclectrocatalysis. In particular, the systems and methods can provide improved removal of contaminants from water.

IPC Classes  ?

• C02F 1/461 - Treatment of water, waste water, or sewage by electrochemical methods by electrolysis
• C02F 1/32 - Treatment of water, waste water, or sewage by irradiation with ultraviolet light
• C02F 1/467 - Treatment of water, waste water, or sewage by electrochemical methods by electrolysis by electrochemical disinfection
• C02F 1/62 - Heavy metal compounds
• C02F 101/20 - Heavy metals or heavy metal compounds
• C02F 101/30 - Organic compounds

Abstract

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of oral bioavailability enhancing formulations of anthelmintic benzimidazole (e.g., oxfendazole) compounds. In particular, the present disclosure provides methods for treating or preventing infectious diseases with one or more oral bioavailability enhancing formulations of anthelmintic benzimidazole (e.g., oxfendazole) compounds, or pharmaceutically acceptable salts thereof, or compositions comprising the same and an additional anti-fungal agent, and pharmaceutical compositions comprising one or more oral bioavailability enhancing formulations of anthelmintic benzimidazole (e.g., oxfendazole) compounds and at least one additional anti-fungal agent.

IPC Classes  ?

• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 9/107 - Emulsions
• A61P 31/10 - Antimycotics
• A61P 33/10 - Anthelmintics

Abstract

Disclosed herein are ligands of formula I or salts thereof, and rare earth metal complexes of the ligands of formula I or salts thereof, Also disclosed herein are devices and materials comprising ligands of formula I or salts thereof, or rare earth metal complexes of the ligands of formula I or salts thereof as well as methods of using the ligands, complexes, devices and materials for detecting ions such as phosphate, methods for removing ions such as phosphate from aqueous solutions or mixtures, and methods for treating hyperphosphatemia. Also disclosed herein are additional ligands and metal complexes thereof as well as uses for these ligands and metal complexes.

IPC Classes  ?

• C07C 229/12 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
• C07D 213/89 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
• C07C 211/65 - Metal complexes of amines
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
• C02F 1/68 - Treatment of water, waste water, or sewage by addition of specified substances, e.g. trace elements, for ameliorating potable water

Abstract

Methods for modulating the release and content of extracellular vesicles from target cells using electrical stimulation are provided. Compositions comprising extracellular vesicles or extracts of extracellular vesicles and methods of administering the compositions to a subject are also provided.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61N 2/00 - Magnetotherapy

Abstract

This disclosure describes, generally, a modified form of CD16, genetically-modified cells that express the modified CD16, and methods that involve the genetically-modified cells. The modified form of CD16 can exhibit increased anti-tumor and/or anti-viral activity due, at least in part, to reduced susceptibility to ADAM17-mediated shedding upon NK cell stimulation.

IPC Classes  ?

• C07K 14/735 - Fc receptors
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 5/0786 - MonocytesMacrophages
• C12N 5/0787 - Granulocytes, e.g. basophils, eosinophils, neutrophils or mast cells

Goods & Services

Fresh apples, excluding crab apples

Abstract

The present document provides methods for post-polymerization modification of polymer backbones. In particular, the methods described in this document relate to transformation of polyesters and polyurethanes via [3,3]-sigmatropic rearrangement. Polymer compounds containing backbones modified post-polymerization are also provided, along with various methods of using these polymers in a variety of segments of the economy.

IPC Classes  ?

• C08G 63/88 - Post-polymerisation treatment
• C08G 18/82 - Post-polymerisation treatment

Abstract

Embodiments are directed to a method for use in ultrasound imaging of matter in a region comprising providing wave energy into the region and transducing wave energy returned from the region to form a set of receive signals defining received signal data. The method comprises separating linear and nonlinear components of the received signal data based on a second order Volterra model. The method also comprises computing an estimate of a tissue acoustic nonlinearity parameter, B/A, using a ratio of the nonlinear component to the linear component, and identifying tissue characteristics of the matter in the region using the B/A.

IPC Classes  ?

• A61B 8/08 - Clinical applications
• G06T 7/00 - Image analysis

Abstract

Methods to activate or enhance phosphorylation of focal adhesion kinase (FAK) are provided herein. Methods to treat epithelial disorders in mammals. namely diseases of the gut. comprising the administration of one or more small molecules having FAK activation properties are also provided.

IPC Classes  ?

• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Abstract

Described herein are methods of recellularizing an organ or tissue matrix.

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
• A61L 27/38 - Animal cells

Abstract

A multimodal method of three-dimensionally (3D) printing a light-emitting diode (LED) display includes extrusion printing a first conductive layer utilizing a first extrusion printing nozzle set, spray printing an active layer onto the first conductive layer utilizing a spray printing nozzle, and extrusion printing a second conductive layer utilizing a second extrusion printing nozzle set.

IPC Classes  ?

• H10K 59/12 - Active-matrix OLED [AMOLED] displays
• H10K 59/131 - Interconnections, e.g. wiring lines or terminals
• H10K 59/80 - Constructional details
• H10K 71/13 - Deposition of organic active material using liquid deposition, e.g. spin coating using printing techniques, e.g. ink-jet printing or screen printing
• H10K 71/60 - Forming conductive regions or layers, e.g. electrodes
• H10K 85/10 - Organic polymers or oligomers
• H10K 102/00 - Constructional details relating to the organic devices covered by this subclass

Abstract

Approaches to stack monolayer transition metal dichalcogenides (TMD) materials to develop near-perfect light absorbers (NPLAs) with only two atomic layers of TMD. Stacking TMDs may result in interlayer coupling with undesirable light absorbing behavior. The NPLAs of this disclosure stacks monolayer TMDs in such a way as to minimize TMD interlayer coupling, thus preserving TMD strong band nesting properties. Examples of approaches in this disclosure control the interlayer coupling by, for example, (a) twisted TMD bi-layers and (b) adding a buffer layer, e.g., a TMD/buffer layer/TMD tri-layer heterostructure. The NPLAs of this disclosure use the band nesting effect in TMDs, combined with a Salisbury screen geometry, to demonstrate NPLAs using only two or three uniform atomic layers of TMDs.

IPC Classes  ?

• G02B 5/00 - Optical elements other than lenses

Abstract

A textile shredder device (100) includes a shred station (102) and a shred chamber (108). The shred station includes a first shred drum (104), a second shred drum (106) and at least one motor. The first shred drum is configured to rotate about a first axis (130) and includes a cylindrical exterior surface (138) having textile shredding teeth (140). The second shred drum is positioned alongside the first shred drum and is configured to rotate about a second axis (132), which is substantially parallel to the first axis. The second shred drum includes a cylindrical exterior surface (138) having textile shredding teeth (140). The shred chamber contains the first and second shred drums and includes a recirculating tray (170) extending along a bottom side (166) of the first and second shred drums and alongside the second shred drum.

IPC Classes  ?

• B02C 4/08 - Crushing or disintegrating by roller mills with two or more rollers with co-operating corrugated or toothed crushing-rollers
• B02C 4/32 - Adjusting, applying pressure to, or controlling the distance between, milling members

Abstract

A frequency-modulated magnetic resonance imaging (MRI) technique uses frequency-modulated radio frequency (RF) pulses to provide spatial encoding without magnetic field gradients. Frequency encoding is provided by using a first frequency- modulated RF pulse to dephase spins. A second frequency-modulated RF pulse is then used to rephase, or refocus, the dephased spins. While the second frequency-modulated RF pulse is generated, k -space data are acquired by sampling one or more echo signals formed during the application of the second frequency-modulated RF pulse. Images may be reconstructed from the k-space data. In some examples, k-space data are transformed into a rotating reference frame using a rotation matrix and images may be reconstructed from the transformed k-space data.

IPC Classes  ?

• G01R 33/483 - NMR imaging systems with selection of signal or spectra from particular regions of the volume, e.g. in vivo spectroscopy
• G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• G01R 33/3875 - Compensation of inhomogeneities using correction coil assemblies, e.g. active shimming

Abstract

Systems, devices, and techniques are configured to determine associations between different genes, gene signatures, and gene ecosystems. In one example, a system includes processing circuitry configured to receive, from a data repository configured to store molecular abundance values for a plurality of samples, one or more matrices comprising at least one molecular abundance value for each sample of the plurality of samples, generate a first correlation matrix by performing a first statistical correlation operation between every pair of columns within the one or more matrices, generate a second correlation matrix by at least performing a second statistical correlation operation between every pair of columns within the first correlation matrix, determine, based on the second correlation matrix, a metric indicative of one or more gene ecosystems for one or more tissue types of at least one sample of the plurality of samples, and output, for display, the metric indicative of the one or more gene ecosystems.

IPC Classes  ?

• G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation
• G06F 16/2457 - Query processing with adaptation to user needs
• G16B 30/10 - Sequence alignmentHomology search

Abstract

Radio frequency ("RF") gradient based magnetic resonance imaging ("MRI") is provided by establishing a gradient in the RF transmit (Bi) field using frequency-modulated RF pulses that are achieved by two or more gradient sets. A phase can be imparted to the magnetic resonance signals, where the phase can comprise of the superposition of the phase imparted by each RF pulse. The parameters of the RF pulses or gradient sets can be chosen to optimize the phase accrual over the imaging volume based on a target phase pattern. The RF pulses can be modified to modify the phase to provide phase encoding of the acquired data. The magnetic resonance signals measured can be reconstructed by standard reconstructions or model-based reconstructions to provide magnetic resonance images without the use of costly and large Bo gradient sets.

IPC Classes  ?

• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
• G01V 33/00 -

Abstract

A system and method for denoising magnetic resonance images (MRI) in a transform domain are provided. In one aspect, the method incudes reconstructing a series of images of the target using the image data, transforming the series of images into a transform domain, and selecting patches in the image domain. The patches can be used to form matrices that can be decomposed to distinguish signal and noise components. Thresholding can be applied to remove the noise components in the transform domain. The denoised data can be inversely transformed back to the image domain to produce denoised images.

IPC Classes  ?

• G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
• G01R 33/561 - Image enhancement or correction, e.g. subtraction or averaging techniques by reduction of the scanning time, i.e. fast acquiring systems, e.g. using echo-planar pulse sequences
• G01R 33/565 - Correction of image distortions, e.g. due to magnetic field inhomogeneities
• G06T 5/10 - Image enhancement or restoration using non-spatial domain filtering
• G06T 5/70 - DenoisingSmoothing

Abstract

A 139-gene epigenetic signature for use in. methods for assessing the age and longevity of a T cell, selecting a T cell for a T cell therapy, and/or determining a T-cell acute lymphoblastic leukemia subtype is provided.

Abstract

The present disclosure provides methamphetamine conjugate, and/or opioid conjugate(s) vaccine compositions and methods thereof. The present disclosure also provides multivalent vaccine compositions.

IPC Classes  ?

• C07C 211/03 - Monoamines
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
• A61P 25/36 - Opioid-abuse

Abstract

The present disclosure relates to stormwater treatment systems for attracting and retaining anaerobic ammonia oxidizing (anammox) bacteria, and methods of treating stormwater including ammonia using such stormwater treatment systems. The anammox bacteria is on carriers including zeolite. Select carriers include zeolite, select carriers do not include zeolite, select carriers are pre-seeded with the anammox bacteria, and select carriers are not pre-seeded with the anammox bacteria. The carriers are installed in the stormwater treatment systems in positions capable of contacting with the stormwater. The stormwater has a variable flow rate, and the system is capable of maintaining anammox bacteria growth when not in contact with the stormwater.

IPC Classes  ?

• C02F 3/30 - Aerobic and anaerobic processes
• C02F 3/10 - PackingsFillingsGrids
• C02F 101/16 - Nitrogen compounds, e.g. ammonia
• C02F 103/00 - Nature of the water, waste water, sewage or sludge to be treated

Abstract

Advances in actuating fabrics could enable a paradigm shift in the field of smart wearables by dynamically fitting themselves to the unique topography of the human body. Active fabrics and fitting mechanisms are described herein that enable garments to conform around surface concavities without requiring high elasticity or a multiplicity of closure devices. Advanced materials and systems innovations (1) enable novel garment manufacturing and application strategies, (2) facilitate topographical fitting (spatial actuation) through garment architectural design, and (3) provide tunable NiTi-based SMA actuation temperatures to enable actuation on the surface of human skin. Such fabrics and garments are usable in a variety of fields including medical compression, technical sportswear, exosuits, space suits and components thereof, or non-garment applications.

IPC Classes  ?

• D04B 1/26 - Weft knitting processes for the production of fabrics or articles not dependent on the use of particular machinesFabrics or articles defined by such processes specially adapted for knitting goods of particular configuration wearing apparel stockings
• A41D 31/18 - Elastic
• A43B 1/04 - Footwear characterised by the material made of fibres or fabrics made therefrom braided, knotted, knitted or crocheted
• A43B 23/02 - UppersBoot legs
• A61F 13/08 - Elastic stockingsBandages or dressingsAbsorbent pads specially adapted for feet or legsCorn-padsCorn-rings for contracting aneurisms
• D04B 1/10 - Patterned fabrics or articles
• D04B 1/18 - Other fabrics or articles characterised primarily by the use of particular thread materials elastic threads
• D04B 1/24 - Weft knitting processes for the production of fabrics or articles not dependent on the use of particular machinesFabrics or articles defined by such processes specially adapted for knitting goods of particular configuration wearing apparel
• D04B 21/06 - Patterned fabrics or articles
• D04B 21/20 - Warp knitting processes for the production of fabrics or articles not dependent on the use of particular machinesFabrics or articles defined by such processes specially adapted for knitting articles of particular configuration

Abstract

A method for monitoring the viability of a megavirus in animal feed or an animal feed ingredient generally includes inoculating the animal feed or animal feed ingredient with a surrogate virus as a proxy for the megavirus, subjecting the animal feed or animal feed ingredient to a treatment that inactivates the megavirus and the surrogate virus, subjecting the animal feed or animal feed ingredient to storage or transportation conditions for at least 14 days, and determining the viability of the surrogate virus in the animal feed or animal feed ingredient, thereby monitoring the viability of the megavirus in the animal feed or animal feed ingredient. In one or more embodiments, the megavirus is African swine fever virus (ASFV) and the surrogate virus is an ASFV surrogate virus. In some of these embodiments, the ASFV surrogate virus is a Coccolithovirus such as, for example, Emiliania huxleyi virus.

IPC Classes  ?

• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
• C12Q 1/6851 - Quantitative amplification

Abstract

The present disclosure provides vaccine compositions that induce opioid specific antibodies.

IPC Classes  ?

• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61K 31/33 - Heterocyclic compounds

Abstract

In some aspects, values of features obtained from training first and second machine-learning models are analyzed to correlate at least a subset of features from the first machine-learning model with at least a subset of features from the second machine-learning model. The correlated features are then applied to update the first or second machine-learning model, or to train a third machine-learning model. In other aspects, a generator machine-learning model processes a seed and a target characteristic indicator to generate a synthetic ECG signal. The synthetic ECG signal is biased according to a target physiological characteristic represented by the target characteristic indicator. The generator machine-learning model can be trained using an expert machine-learning model and in an adversarial process with a discriminator machine-learning model.

IPC Classes  ?

• G06N 3/08 - Learning methods
• A61B 5/319 - Circuits for simulating ECG signals
• A61B 5/35 - Detecting specific parameters of the electrocardiograph cycle by template matching

Abstract

The present invention relates to compositions suitable for the transdermal, transmembrane, transmucosal, and/or transtympanic administration of a therapeutically effective amount of a therapeutic compound such as an antibiotic for treating a subject, wherein the delivery of the therapeutic compound is enhanced by forming a pseudo- surfactant assembly with a first compound comprising a chemical penetration enhancer.

IPC Classes  ?

• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Abstract

Neurostimulation, such as electrical and/or magnetic neurostimulation, is controlled using an adaptive real-time state space (ARTISTS) control framework to determine and/or adjust stimulation settings (e.g., stimulation waveforms). The ARTISTS control framework generally includes an adaptive autoregressive model of the nervous system's response to stimulation, an amended Kalman filter to estimate the state and coefficients of the autoregressive model, and a linear quadratic regulator to determine the stimulation waveform to be delivered.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers

Abstract

The present disclosure generally relates to Camelina sativa plants exhibiting facultative wintering. Provided herein are methods and compositions for producing plants exhibiting facultative wintering. Also provided herein are exemplary plants exhibiting this trait, including, for example, Camelina sativa line ‘CMN2207’.

IPC Classes  ?

• A01H 6/20 - Brassicaceae, e.g. canola, broccoli or rucola
• A01H 5/10 - Seeds

Abstract

A composition generally includes a virus-like particle (VLP) and a truncated form of a viral envelope protein displayed on the VLP. Generally, the truncated form of the envelope protein has at least a portion of the cytoplasmic tail region of the envelope protein deleted. The VLP may be generated by transfection with a first polynucleotide that encodes a VLP subunit protein and second polynucleotide that encodes the truncated envelope protein. The transfection may be performed in vitro or in vivo.

IPC Classes  ?

• A61K 39/21 - Retroviridae, e.g. equine infectious anemia virus
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 9/51 - Nanocapsules
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/14 - Antivirals for RNA viruses
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

A system for modifying dairy protein functionality can include a milk protein input, a treatment process, and a milk protein output. A controller can be in communication with the treatment process and can be configured to receive one or more input parameters. The controller can generate one or more treatment parameters based on the one or more input parameters. The controller can then initiate the treatment process based on one or more of the treatment parameters. The modified dairy protein functionality can be selected or optimized based on a target functionality of the milk protein output.

IPC Classes  ?

• A23J 3/08 - Dairy proteins
• A23C 9/14 - Milk preparationsMilk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
• A23C 9/144 - Milk preparationsMilk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by electrical means, e.g. electrodialysis
• A23J 3/10 - Casein

Abstract

in vitroin vitroin vitro dental calculus model includes applying saliva to a dental substrate in a production environment (step 90), applying a mixture of an extracellular support material and at least one bacterial species to the dental substrate (step 92), applying a solution comprising calcium and phosphate to the mixture on the dental substrate (step 94), and removing the dental substrate from the production environment after a period of time during which a mineralized biofilm comprising the extracellular support material and the at least one bacterial species forms on the dental substrate (step 96).

IPC Classes  ?

• G09B 23/28 - Models for scientific, medical, or mathematical purposes, e.g. full-sized device for demonstration purposes for medicine
• C12Q 1/18 - Testing for antimicrobial activity of a material

Abstract

In general, the disclosure is directed to bulk iron-nitride materials having a polycrystalline microstructure having pores including a plurality of crystallographic grains surrounded by grain boundaries, where at least one crystallographic grain includes an iron-nitride phase including any of a body centered cubic (bcc) structure, a body centered tetragonal (bct), and a martensite structure. The disclosure further describes techniques producing a bulk iron-nitride material having a polycrystalline microstructure, including: melting an iron source to obtain a molten iron source; fast belt casting the molten iron source to obtain a cast iron source; cooling and shaping the cast iron source to obtain a bulk iron-containing material having a body-centered cubic (bcc) structure; annealing the bulk iron-containing material at an austenite transformation temperature and subsequently cooling the bulk iron-containing material; and nitriding the bulk iron-containing material to obtain the bulk iron-nitride material.

IPC Classes  ?

• H01F 1/047 - Alloys characterised by their composition
• C01B 21/06 - Binary compounds of nitrogen with metals, with silicon, or with boron
• C23C 8/02 - Pretreatment of the material to be coated
• C23C 8/26 - Nitriding of ferrous surfaces
• H01F 41/02 - Apparatus or processes specially adapted for manufacturing or assembling magnets, inductances or transformersApparatus or processes specially adapted for manufacturing materials characterised by their magnetic properties for manufacturing cores, coils or magnets

Abstract

This disclosure describes an adaptive NK cell, an isolated population of adaptive Natural Killer (NK) cells, a composition including an adaptive NK cell, and methods for producing, preparing, and using an adaptive NK cell or an isolated population or composition including an adaptive NK cell. The adaptive NK cells may be used to treat a viral infection or a tumor.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/245 - Herpetoviridae, e.g. herpes simplex virus
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

Systems, devices, and techniques are configured to leverage acoustic-based microfluidic amplification for the detection of a biological substance, such as misfolded proteins associated with a protein-misfolding disease. In one example, a system (100) includes a housing defining a main channel (104) configured to contain a fluid solution containing a sample including a plurality of proteins and one or more side channels (106) in fluid communication with the main channel, wherein each side channel of the one or more side channels are configured to establish a liquid-gas interface (108) between the fluid solution in the main channel and air contained in the one or more side channels. The systems may also include at least one acoustic generation element configured to generate acoustic waves within the air of the one or more side channels that causes vibration of the liquid-gas interface and mixing of the fluid solution within the main channel.

IPC Classes  ?

• B01F 31/65 - Mixers with shaking, oscillating, or vibrating mechanisms the materials to be mixed being directly submitted to a pulsating movement, e.g. by means of an oscillating piston or air column
• B01F 31/87 - Mixing by means of high-frequency vibrations above one kHz, e.g. ultrasonic vibrations transmitting the vibratory energy by means of a fluid, e.g. by means of air shock waves
• B01F 33/30 - Micromixers
• G01N 1/38 - Diluting, dispersing or mixing samples
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances

Abstract

The invention provides a compound of formula (I): or a salt thereof, wherein A, B, C, R1, and R have any of the values described in the specification, as well as compositions comprising a compound of formula (I). The compounds are useful for agonizing the activity of PPARα and for treating diseases modulated by PPARα, such as, for example, diabetic retinopathy, pain, and liver diseases including fibrosis, NASH and NAFLD. Certain compounds are also useful as both agonists of PPARα and inhibitors of STING.

IPC Classes  ?

• C07D 249/06 - 1,2,3-TriazolesHydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
• C07D 277/28 - Radicals substituted by nitrogen atoms
• C07D 213/36 - Radicals substituted by singly-bound nitrogen atoms
• C07C 229/60 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in meta- or para- positions
• A61P 27/02 - Ophthalmic agents

Abstract

A modified virus includes a targeting motif including the amino acid sequence (G/S)TM(G/H)(T/A)S(H/R), wherein the targeting motif selectively binds to prostate specific membrane antigen (PSMA). In one or more embodiments, the modified virus is an adenovirus. In one or more embodiments, the targeting motif has the amino acid sequence of any one of SEQ ID NOs:11-18. In one or more embodiments, a method of administrating a modified virus includes administering the modified virus via intravenous, intratumoral, or systemic injection.

IPC Classes  ?

• A61K 35/761 - Adenovirus
• A61P 35/00 - Antineoplastic agents
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids

Goods & Services

(1) Apple trees; live trees

Abstract

The present invention provides efficient methods for producing genetically modified natural killer (NK) cells using a base editor and guide RNA(s). Genetically modified NK cells produced by these methods and the use of these cells in the treatment of cancer are also provided.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• C12N 9/22 - Ribonucleases
• C12N 9/78 - Hydrolases (3.) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

Precision functional mapping (PFM) is used to inform the planning, guidance, and/or monitoring of neuromodulation, including non-invasive brain stimulation, deep brain stimulation, prefrontal cortical stimulation, intracranial electrical stimulation, focused ultrasound-based neuromodulation, pharmacological-based neuromodulation, or the like.

IPC Classes  ?

• G16H 20/30 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
• G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof

Abstract

Subject-specific energy distribution mapping of functional networks is used to inform the planning, guidance, and/or monitoring of neuromodulation, including non-invasive brain stimulation, deep brain stimulation, prefrontal cortical stimulation, intracranial electrical stimulation, focused ultrasound-based neuromodulation, pharmacological-based neuromodulation, or the like.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61N 2/00 - Magnetotherapy
• G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
• G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation

Abstract

Provided herein is an infectious recombinant adeno-associated virus (rAAV), comprising a modified viral capsid and a viral genome, wherein the modified viral capsid comprises one or more insertions of amino acids that includes one or more single stranded nucleic acid binding domains, one or more small binding proteins or a combination thereof at a residue from 260 to 270, 328 to 338, 370 to 400 or 618 to 727 of VP1 residues.

IPC Classes  ?

• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C07K 14/075 - Adenoviridae
• C12N 9/22 - Ribonucleases
• C12N 15/86 - Viral vectors

Abstract

A pharmaceutical composition for administering directly to the pulmonary tract of a subject includes a salt of triiodothyronine and a pharmaceutically acceptable buffer, adjusted to a pH of 5.5-8.5. The composition can be administered prophylactically or therapeutically to a subject to treat lung inflammation or pulmonary edema.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

Disclosed herein are methods and systems for burning gaseous ammonia, including receiving a oxidizer gas into a chamber body such that the oxidizer gas generally flows in direction that extends along a longitudinal axis of the chamber body; introducing gaseous ammonia into the chamber body such that swirl is introduced into the gaseous ammonia; mixing the oxidizer gas and the gaseous ammonia to form a combustion mixture; igniting the combustion mixture; and combusting the combustion mixture for a duration such that the gaseous ammonia is converted to combustion products.

IPC Classes  ?

• F23D 14/02 - Premix gas burners, i.e. in which gaseous fuel is mixed with combustion air upstream of the combustion zone
• F23C 1/00 - Combustion apparatus specially adapted for combustion of two or more kinds of fuel simultaneously or alternately, at least one kind of fuel being either a fluid fuel or a solid fuel suspended in air
• F23C 9/00 - Combustion apparatus characterised by arrangements for returning combustion products or flue gases to the combustion chamber
• F23D 14/64 - Mixing devicesMixing tubes with injectors
• F23D 23/00 - Assemblies of two or more burners
• F23K 5/00 - Feeding or distributing other fuel to combustion apparatus

Abstract

Example artificial dental calculus models are described. In one example, an in vitro artificial dental calculus includes a dental substrate and a mineralized biofilm comprising an extracellular support material and at least one bacterial species. In one example, a method for creating an in vitro dental calculus model includes applying saliva to a dental substrate in a production environment, applying a mixture of an extracellular support material and at least one bacterial species to the dental substrate, applying a solution comprising calcium and phosphate to the mixture on the dental substrate, and removing the dental substrate from the production environment after a period of time during which a mineralized biofilm comprising the extracellular support material and the at least one bacterial species forms on the dental substrate.

IPC Classes  ?

• G09B 23/28 - Models for scientific, medical, or mathematical purposes, e.g. full-sized device for demonstration purposes for medicine

Abstract

This document relates to methods and materials for detecting the presence or absence of misfolded polypeptides in a sample. For example, a sample (e.g., a biological sample or an environmental sample) can be exposed to nanoparticles (e.g., nanoparticles having a size of no more than 2 μm (e.g., no more than 1 μm) such as silica nanoparticles (siNPs) having a size of no more than 2 μm (e.g., siNPs having a size of no more than 1 μm)) during a seeded amplification assay to accelerate the aggregation of misfolded polypeptides present in the sample into fibrils and/or polypeptide aggregates (e.g., globular polypeptide aggregates). In some cases, methods and materials provided herein can be used to determine if a mammal (e.g., a human) has a proteinopathy based, at least in part, in the presence or absence of misfolded polypeptides in a sample obtained from the mammal.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• B82Y 15/00 - Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors

Abstract

A stable mammalian cell line includes a first polynucleotide encoding a first AAV inverted terminal repeat (ITR) sequence. In one or more embodiments, the first polynucleotide includes a first inducible promoter. The stable mammalian cell line may further include a second polynucleotide encoding a repressor, wherein the first inducible promoter is operably linked to the repressor. A method of using a stable mammalian cell line includes contacting the stable mammalian cell line with an inducer. A polynucleotide encodes a first AAV inverted terminal repeat (ITR) sequence, a first inducible promoter, and a repressor.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/861 - Adenoviral vectors
• C12N 15/864 - Parvoviral vectors
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 21/64 - FluorescencePhosphorescence

Abstract

Methods for making thin wall balloons or bladders. Methods of the present disclosure provide for the manufacture of medical balloon devices (150) from a singular elastic material, for example double walled balloons useful as vessel implants. In some non-limiting examples, the medical device balloon is formed by 3D printing. The methods of the present disclosure are customizable for individual patients and can generate medical balloon devices that can be used as venous or aortic stent-graft devices.

IPC Classes  ?

• B29C 64/106 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material
• A61F 2/07 - Stent-grafts
• A61M 25/10 - Balloon catheters
• B29C 64/264 - Arrangements for irradiation
• B29C 64/40 - Structures for supporting 3D objects during manufacture and intended to be sacrificed after completion thereof
• B33Y 10/00 - Processes of additive manufacturing
• B33Y 80/00 - Products made by additive manufacturing

Abstract

The present invention provides compositions that include an extract of human feces, and methods for using such compositions, including methods for replacing or supplementing or modifying a subject's colon microbiota, and methods for treating a disease, pathological condition, and/or iatrogenic condition of the colon.

IPC Classes  ?

• A61K 35/37 - Digestive system
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
• A61K 35/24 - MucusMucous glandsBursaSynovial fluidArthral fluidExcretaSpinal fluid
• A61K 35/74 - Bacteria
• A61K 35/741 - Probiotics
• A61K 35/742 - Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 47/08 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Abstract

The invention provides a compound of formula (I): The invention provides a compound of formula (I): The invention provides a compound of formula (I): or a salt thereof, wherein R1, R2, R3, B, X, and Y have any of the values described in the specification, as well as compositions comprising a compound of formula (I). The compounds are useful as TET inhibitors, epigenetic modulators, and for treating cancer, eating disorders, and as adjuvants in cancer immunotherapy.

IPC Classes  ?

• C07H 19/073 - Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid

Abstract

An RNA-binding protein includes a substitution mutation to a semi-conserved domain, said semi-conserved domain including the amino acid sequence of SEQ ID NO:5. 21. The RNA-binding protein may be an HUH endonuclease, such as a virally-derived HUH endonuclease, such as PCV2. A fusion protein includes an RNA-binding protein and a protein involved in gene editing. A composition includes an RNA-binding protein or a fusion protein including an RNA-binding protein.

IPC Classes  ?

• C07K 14/01 - DNA viruses
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C12N 9/22 - Ribonucleases

Abstract

Devices, systems, and techniques are described for creating pre-aligned cells in fibers to be wound into tissue constructs or microtissues that can be printed into larger tissue constructs. For example, a method includes dispensing a biological fiber into a solution, wherein the biological fiber comprises a plurality of cells within a hydrogel. The method may then include spooling, under tension, the biological fiber from the solution and onto a spool structure. In some examples, the method may also include winding the biological fiber around a tissue frame to create a tissue construct or cutting the biological fiber matured into a pre-aligned microtissue from the spool structure and used in a bioink for printing tissue constructs.

IPC Classes  ?

• A61L 27/52 - Hydrogels or hydrocolloids
• B33Y 10/00 - Processes of additive manufacturing
• B33Y 70/00 - Materials specially adapted for additive manufacturing
• B33Y 80/00 - Products made by additive manufacturing
• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

A wheelchair having a frame, a footplate that is coupled to the frame and movable relative to the frame about and between a lowered position and a raised position, and a lever that permits actuation of the footplate about and between the lowered position and the raised position. Also disclosed is a wheelchair having a pair of drive wheels, at least one motor, wherein each motor of the at least one motor coupled to a respective drive wheel of the pair of drive wheels, at least one sensor. A controller is in communication with the at least one sensor and each motor of the at least one motor. The controller is configured to control operation of the motor based on input from the at least one sensor.

IPC Classes  ?

• A61G 5/08 - Chairs or personal conveyances specially adapted for patients or disabled persons, e.g. wheelchairs foldable

Abstract

Restraining systems and devices for deployment or placement over a prone or supine subject's upper torso and/or limbs. Upper torso restraining devices (20) have a shell-like shape, defining an interior region sized and shaped to receive an upper torso of a human adult subject. The upper torso restraining device is sized and shaped to pin or contain the subject relative to a supporting surface and has a sufficiently robust construction such that a user can safely place her or his weight on a breastplate surface to prevent the subject from moving. Where appropriate, the restraining device can be strapped or secured to the supporting surface. Limb restraining devices are configured to be applied about or around a joint of a subject. Restraining systems can include the upper torso restraining device and one or more of the limb restraining devices.

IPC Classes  ?

• A61F 5/37 - Restraining devices for the body or for body partsRestraining shirts
• E05B 75/00 - Handcuffs

Abstract

Embodiments comprise an electrocardiograph device for detecting electrical signals of a ventricular fibrillation event in a patient and producing ECG data, a classifier, and a display device. The classifier comprises a memory and a processor, the memory storing a model and one or more parameters of the model. The memory further stores instructions that when executed by the processor the processor to receive the ECG data, and generate a determination indicating whether the ventricular fibrillation event has been caused by heart muscle ischemia based on the model, the parameters of the model. The display device is configured to output the determination, which can also be communicated to follow-on provider systems. The determination can also indicate a predicted coronary perfusion pressure.

IPC Classes  ?

• A61N 1/39 - Heart defibrillators

Abstract

A neurostimulator incorporating a novel chip design that uses the principle of redundant signal crossfiring to overcome electronic component mismatch error in general and transistor mismatch error in particular, to yield superior quality neurostimulation signal generation, useful in enhancing the bidirectional human-machine interface in prosthesis operation for the restoration of somatosensation for an amputee.

IPC Classes  ?

• A61F 2/72 - Bioelectric control, e.g. myoelectric
• A61F 2/50 - Prostheses not implantable in the body
• A61F 2/54 - Artificial arms or hands or parts thereof
• A61F 2/58 - ElbowsWrists
• A61F 2/68 - Operating or control means
• A61F 2/70 - Operating or control means electrical
• H03M 1/66 - Digital/analogue converters

Abstract

Systems and methods for analyzing powder compaction data to extract or derive parameters of the powder. With methods of the present disclosure, in-die compaction simulator data is collected and analyzed, and requires only a relatively small quantity of material. The systems and methods can utilize an additive mathematical model of powder compressibility during uniaxial compaction by combining bulk elasticity, linear and non-linear, and low-to-medium pressure densification processes for assessing a powder material under consideration.

IPC Classes  ?

• G01N 3/08 - Investigating strength properties of solid materials by application of mechanical stress by applying steady tensile or compressive forces
• G01N 19/00 - Investigating materials by mechanical methods
• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups

Abstract

Certain embodiments of the invention provide conjugates, chemically self-assembled nanoring (CSAN), and cell modified with CSAN as described herein. Certain embodiments of the invention provide a method for cell-based drug delivery. Certain embodiments of the invention provide a method of transferring a cargo from a sender cell to a receiver cell as described herein.

IPC Classes  ?

• C12N 9/06 - Oxidoreductases (1.), e.g. luciferase acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

A musical composition is varied using a computational model of rubato. Rubato is modeled by changes to the symbolic onset and/or symbolic offset of each note, which allows for a greater flexibility in timing modifications, such as asymptotic tempo and localized retrogrades. A user selects notes to be modified (e.g., by plotting points to modify notes over a selected interval), and a curve fitting (e.g., a cubic spline interpolation) is used to determine modifications for other notes in the composition. These symbolic onset/offset modifications may also be translated into tempo modifications. The symbolic onset and/or offset modifications are applied to the composition to produce an adjusted musical composition, to which rubato has been applied. Rubato profiles can similarly be extracted from existing musical recordings and used to characterize the recordings, such as for training machine learning models and recommender systems.

IPC Classes  ?

• G10H 1/00 - Details of electrophonic musical instruments

Abstract

Systems and methods for producing and using an e-textile are described herein that use connectors to create an electronic connectivity in any of a number of desired patterns or positions across the e-textile. These systems and methods can use a multi-layer e-textile that includes an insulating layer, a conductive layer, and a connector.

IPC Classes  ?

• A41D 1/00 - Garments
• A41D 19/00 - Gloves
• D03D 1/00 - Woven fabrics designed to make specified articles
• H05K 1/03 - Use of materials for the substrate

Abstract

Systems and methods for producing and using an e-textile actuator including a coverstitch in the e-textile and including a top looper, a bottom looper, and a needle thread, wherein at least one of the top looper, the bottom looper, and the needle thread comprises a shape memory material such as a shape memory alloy.

IPC Classes  ?

• A41D 13/12 - Surgeons' or patients' gowns or dresses
• D04B 1/12 - Patterned fabrics or articles characterised by thread material
• D04B 21/16 - Fabrics characterised by the incorporation by knitting, in one or more thread, fleece, or fabric layers, of reinforcing, binding, or decorative threadsFabrics incorporating small auxiliary elements, e.g. for decorative purposes incorporating synthetic threads
• D04B 23/12 - Flat warp knitting machines with provision for incorporating unlooped wefts extending from selvedge to selvedge

Abstract

Automated wheel loader control system architectures, and corresponding control systems and methods for automated wheel loaders. The control architecture includes an engine speed controller, a vehicle speed controller, a bucket lift speed controller, a bucket tilt speed controller, and a steering controller. The controllers are decoupled from one another. Engine speed, vehicle speed, lift speed, tilt speed and vehicle position signals are used to affect engine throttle, brake pedal, lift valve command, tilt valve command, and steering wheel speed, respectively, to track desired reference signals. The control architecture is formatted such that desired engine speed must be generated, while the other reference signals are inputs to the system. Regardless, the reference profile for each subsystem is generated by corresponding optimization algorithms.

IPC Classes  ?

• E02F 3/34 - DredgersSoil-shifting machines mechanically-driven with digging tools mounted on a dipper- or bucket-arm, e.g. dippers, buckets with bucket-arms directly pivoted on the frames of tractors or self-propelled machines
• E02F 3/342 - Buckets emptying overhead
• E02F 9/20 - DrivesControl devices

Abstract

Disclosed herein are methods and systems for operating a combustion engine, including: introducing, during an intake stroke of an internal combustion engine, a first volume of a fuel including ammonia into a pre-chamber, and a primary charge fluid into a main chamber; compressing, during a compression stroke of the internal combustion engine, the air into the pre-chamber such that the first volume of the fuel and the air form a compressed mixture; introducing, following the compression stroke, a second volume of the fuel into the compressed mixture to form a rich mixture; igniting the rich mixture in the pre-chamber; flowing, during a power stroke of the internal combustion engine, the ignited rich mixture into the main chamber; and exhausting the main chamber.

Abstract

A device and system for producing a skin displacement experience for a user. The device includes a base, one or more actuators, each actuator including a shape memory alloy (SMA) coil and at least one eye, at least one attachment point mounted on the base and engaging with the at least one eye, and a skin interface mounted on the base and responsive to the one or more actuators at the at least one attachment point.

IPC Classes  ?

• G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer
• A61H 1/00 - Apparatus for passive exercisingVibrating apparatusChiropractic devices, e.g. body impacting devices, external devices for briefly extending or aligning unbroken bones

Abstract

A platform for biocomputing technology including a plurality of logic gates for operation in a cell-free environment using DNA, enzymes, and transcriptional RNA aptamer outputs for controlling one or more biological reactions to form RNA or protein products and a platform for the designing and verifying of a plurality of Boolean logic gates.

IPC Classes  ?

• G06N 3/00 - Computing arrangements based on biological models
• G16B 50/30 - Data warehousingComputing architectures

Abstract

Embodiments herein relate to breath analysis system. In an embodiment, a gas measurement device is included having a housing defining an interior volume. The housing can include a fluid ingress port, a fluid egress port, a bottom wall, and a circuit board disposed within the interior volume. The circuit board can include a first side and a second side, where the first side of the circuit board faces inward toward the interior volume. The circuit board can include a plurality of gas sensors disposed on the first side of the circuit board and a plurality of conductive pads disposed on the second side of the circuit board, wherein a plurality of electrical contacts contact the conductive pads when the circuit board is seated within the housing. Other embodiments are also included herein.

IPC Classes  ?

• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
• G01N 27/447 - Systems using electrophoresis
• G01N 27/70 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosolsInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electric discharges, e.g. emission of cathode using electric discharge to ionise a gas and measuring current or voltage

Abstract

A method to prevent, inhibit the progression of, reduce the severity of, or treat cardiac, vascular or skeletal dysfunction or defect(s) in a human having lysosomal storage disorder, is provided.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• A61P 3/06 - Antihyperlipidemics
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 19/00 - Drugs for skeletal disorders
• C12N 15/86 - Viral vectors

Abstract

Mass spectrometry samples and mass spectrometry methods. Mass spectrometry samples include a first cell fraction, a second cell fraction, a reference cell fraction, and a target polypeptide. The target polypeptide include at least a portion of the amino acid sequence of a polypeptide of interest. Polypeptides in each cell fraction and the target polypeptides are labeled with a tandem mass tag.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• H01J 49/00 - Particle spectrometers or separator tubes
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

A method of suspended particle detection includes receiving, with a particle concentrator, an aerosol comprising particles suspended within a bulk gas. The aerosol has a first concentration indicative of count of particles per unit volume of the bulk gas. The method includes concentrating, with the particle concentrator, the aerosol to generate a particle-rich stream of gas comprising at least one particle. The particle-rich stream of gas has a second concentration greater than the first concentration. The method includes irradiating the at least one particle in the particle-rich stream of gas with a light source of a certain wavelength in a detection chamber, and capturing image data relating to the at least one particle with an image sensor located within the detection chamber.

IPC Classes  ?

• G01N 15/0227 - Investigating particle size or size distribution by optical means using imagingInvestigating particle size or size distribution by optical means using holography
• G01N 1/22 - Devices for withdrawing samples in the gaseous state
• G01N 1/40 - Concentrating samples
• G01N 15/00 - Investigating characteristics of particlesInvestigating permeability, pore-volume or surface-area of porous materials
• G01N 15/1434 - Optical arrangements

Abstract

A neonatal pneumothorax decompression device is disclosed. The device comprises a needle stabilizer, a pressure indicator, and a fluid evacuation pump. The needle stabilizer is configured to facilitate insertion of the needle into a subject's pleural cavity and to hold a needle at an adjustable length. The pressure indicator is coupled to the proximal end of the needle stabilizer and is configured to visibly display pressure within the subject's pleural cavity. The fluid evacuation pump is configured to be actuated by a user to evacuate air or fluid from the subject's pleural cavity through the needle. The fluid evacuation pump is proximally coupled to the pressure indicator and the needle stabilizer.

IPC Classes  ?

• A61B 17/34 - TrocarsPuncturing needles
• A61B 17/00 - Surgical instruments, devices or methods
• A61M 1/04 - Pneumothorax apparatus